DNM1L and lung adenocarcinoma: Furthermore, since DRP1 might not be a suitable therapeutic target due to the crucial role of mitochondrial dynamics in cellular adaptations [1], the biosynthetic alterations after DRP1 depletion might suggest potential metabolism‐related therapeutic targets in lung adenocarcinoma.